355 related articles for article (PubMed ID: 21274888)
1. Hepatocyte-specific magnetic resonance imaging contrast agents.
Fidler J; Hough D
Hepatology; 2011 Feb; 53(2):678-82. PubMed ID: 21274888
[No Abstract] [Full Text] [Related]
2. Magnetic resonance imaging of focal liver lesions: approach to imaging diagnosis.
Fowler KJ; Brown JJ; Narra VR
Hepatology; 2011 Dec; 54(6):2227-37. PubMed ID: 21932400
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC
J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
[TBL] [Abstract][Full Text] [Related]
4. Focal nodular hyperplasia: typical and atypical MRI findings with emphasis on the use of contrast media.
Marin D; Brancatelli G; Federle MP; Lagalla R; Catalano C; Passariello R; Midiri M; Vilgrain V
Clin Radiol; 2008 May; 63(5):577-85. PubMed ID: 18374723
[TBL] [Abstract][Full Text] [Related]
5. MRI features of inflammatory hepatocellular adenomas on hepatocyte phase imaging with liver-specific contrast agents.
Thomeer MG; Willemssen FE; Biermann KK; El Addouli H; de Man RA; Ijzermans JN; Dwarkasing RS
J Magn Reson Imaging; 2014 May; 39(5):1259-64. PubMed ID: 23897798
[TBL] [Abstract][Full Text] [Related]
6. Gadoxetic acid-enhanced hepatobiliary phase MR imaging: cellular insight.
Pastor CM
Radiology; 2010 Nov; 257(2):589. PubMed ID: 20959554
[No Abstract] [Full Text] [Related]
7. Characteristics and distinguishing features of hepatocellular adenoma and focal nodular hyperplasia on gadoxetate disodium-enhanced MRI.
Purysko AS; Remer EM; Coppa CP; Obuchowski NA; Schneider E; Veniero JC
AJR Am J Roentgenol; 2012 Jan; 198(1):115-23. PubMed ID: 22194486
[TBL] [Abstract][Full Text] [Related]
8. Imaging of paediatric liver tumours with pathological correlation.
Das CJ; Dhingra S; Gupta AK; Iyer V; Agarwala S
Clin Radiol; 2009 Oct; 64(10):1015-25. PubMed ID: 19748008
[TBL] [Abstract][Full Text] [Related]
9. MRI findings of hepatocellular carcinoma.
Wiwanitkit V
Magn Reson Imaging; 2011 Feb; 29(2):303. PubMed ID: 21129874
[No Abstract] [Full Text] [Related]
10. [Gd-EOB-DTPA-enhanced magnetic resonance imaging: differentiation between focal nodular hyperplasia and hepatocellular adenoma].
Portilha MA; Pedro MT; Ruivo C; Semedo LC; Marques C; Alves FC
Acta Med Port; 2011 Dec; 24 Suppl 2():531-8. PubMed ID: 22849944
[TBL] [Abstract][Full Text] [Related]
11. Primary hepatocellular lesions: imaging findings on state-of-the-art magnetic resonance imaging, with pathologic correlation.
van den Bos IC; Hussain SM; de Man RA; Zondervan PE; Ijzermans JN; Krestin GP
Curr Probl Diagn Radiol; 2008; 37(3):104-14. PubMed ID: 18436110
[TBL] [Abstract][Full Text] [Related]
12. MRI findings of rapidly progressive hepatocellular carcinoma.
Kierans AS; Leonardou P; Hayashi P; Brubaker LM; Elazzazi M; Shaikh F; Semelka RC
Magn Reson Imaging; 2010 Jul; 28(6):790-6. PubMed ID: 20427139
[TBL] [Abstract][Full Text] [Related]
13. The role of hepatocyte-specific contrast agents in hepatobiliary magnetic resonance imaging.
Burke C; Alexander Grant L; Goh V; Griffin N
Semin Ultrasound CT MR; 2013 Feb; 34(1):44-53. PubMed ID: 23395317
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic accuracy of MRI in differentiating hepatocellular adenoma from focal nodular hyperplasia: prospective study of the additional value of gadoxetate disodium.
Bieze M; van den Esschert JW; Nio CY; Verheij J; Reitsma JB; Terpstra V; van Gulik TM; Phoa SS
AJR Am J Roentgenol; 2012 Jul; 199(1):26-34. PubMed ID: 22733890
[TBL] [Abstract][Full Text] [Related]
15. Characterization of cirrhotic nodules with gadoxetic acid-enhanced magnetic resonance imaging: the efficacy of hepatocyte-phase imaging.
Chou CT; Chen YL; Su WW; Wu HK; Chen RC
J Magn Reson Imaging; 2010 Oct; 32(4):895-902. PubMed ID: 20882620
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of Gd-BOPTA and Gd-DTPA in contrast-enhanced MR imaging of the liver].
Zhang HM; Ouyang H; Zhou CW
Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):111-5. PubMed ID: 16750014
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents.
Goodwin MD; Dobson JE; Sirlin CB; Lim BG; Stella DL
Radiographics; 2011 Oct; 31(6):1547-68. PubMed ID: 21997981
[TBL] [Abstract][Full Text] [Related]
18. Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update.
Bioulac-Sage P; Balabaud C; Bedossa P; Scoazec JY; Chiche L; Dhillon AP; Ferrell L; Paradis V; Roskams T; Vilgrain V; Wanless IR; Zucman-Rossi J;
J Hepatol; 2007 Mar; 46(3):521-7. PubMed ID: 17239484
[No Abstract] [Full Text] [Related]
19. Liver lesion characterization: the wrong choice of contrast agent can mislead the diagnosis of hemangioma.
Pradella S; Lucarini S; Colagrande S
AJR Am J Roentgenol; 2012 Nov; 199(5):W662. PubMed ID: 23096214
[No Abstract] [Full Text] [Related]
20. [Hepatocyte targeted MR contrast agent--Gd-BOPTA(E-7155)].
Kuwatsuru R; Katayama H
Nihon Rinsho; 2001 Oct; 59 Suppl 6():323-7. PubMed ID: 11761966
[No Abstract] [Full Text] [Related]
[Next] [New Search]
